G Weil-Hillman
About
In The Last Decade
G Weil-Hillman
16 papers receiving 436 citations
Peers
Comparison fields: 5 of 54
- Immunology 342
- Oncology 163
- Molecular Biology 103
- Radiology, Nuclear Medicine and Imaging 62
- Biotechnology 42
Countries citing papers authored by G Weil-Hillman
This map shows the geographic impact of G Weil-Hillman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Weil-Hillman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Weil-Hillman more than expected).
Fields of papers citing papers by G Weil-Hillman
This network shows the impact of papers produced by G Weil-Hillman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Weil-Hillman. The network helps show where G Weil-Hillman may publish in the future.
Co-authorship network of co-authors of G Weil-Hillman
This figure shows the co-authorship network connecting the top 25 collaborators of G Weil-Hillman. A scholar is included among the top collaborators of G Weil-Hillman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G Weil-Hillman. G Weil-Hillman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 17 | |
| 2 | 48 | |
| 3 | 23 | |
| 4 | Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy. | 6 |
| 5 | Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. | 27 |
| 6 | 9 | |
| 7 | 18 | |
| 8 | Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity. | 19 |
| 9 | Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. | 76 |
| 10 | The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment. | 55 |
| 11 | Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients. | 17 |
| 12 | In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2. | 65 |
| 13 | Combined immunochemotherapy of human solid tumors in nude mice. | 31 |
| 14 | Visualization of the fate of inactive influenza viruses in Daudi cells by electron microscopy. | 4 |
| 15 | Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model. | 32 |
| 16 | Arrest of Daudi cell growth by inactive influenza virus in-vitro. | 5 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.